Neoadjuvant camrelizumab, nab-paclitaxel, and carboplatin in patients with stage IB-IIIA non-small cell lung cancer (NANE-LC): a study protocol of prospective, single-arm, multicenter, phase II study

BACKGROUND: Previous studies have shown that neoadjuvant immune checkpoint inhibitors (ICIs) combined with chemotherapy in patients with stage IB–IIIA non-small cell lung cancer (NSCLC) significantly improved the major pathological response (MPR) and the pathological complete response (pCR) rates. H...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Haiyu, Lin, Lili, Qin, Tao, Ren, Wei, Tan, Yujie, Yang, Qiong, Xu, Huixin, Xie, Xinxin, Chen, Yongjian, Liu, Shengbo, Li, Xing, Li, Zhihua, Hu, Hai, Yu, Yunfang, Yao, Herui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8662502/
https://www.ncbi.nlm.nih.gov/pubmed/34992825
http://dx.doi.org/10.21037/jtd-21-1022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8662502/
https://www.ncbi.nlm.nih.gov/pubmed/34992825
http://dx.doi.org/10.21037/jtd-21-1022

Ejemplares similares